SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trinity Biotech plc (TRIB)

NEW YORK, March 1, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Trinity Biotech plc ("Trinity" or the "Company") (NASDAQ: TRIB). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/trib.

The investigation concerns whether Trinity and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Trinity's On October 4, 2016 Trinity revealed that it was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer following the U.S. Food and Drug Administration's recommendation. Following this news, Trinity stock dropped over 50% to close at just $6.46 per share on October 4, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Trinity, you can assist this investigation by visiting the firm's site: www.bgandg.com/trib. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

http://www.bgandg.com